Leukemia and Lymphoma

The AJMC® Leukemia & Lymphoma compendium is a comprehensive resource for clinical news and expert insights for the blood cancers and their treatments.

Latest News
July 14th 2025

Obe-Cel Is Effective Irrespective of Age in Relapsed/Refractory B-ALL

January 13th 2025

Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients

June 18th 2024

BrECADD Regimen Reaches “Unprecedently High” PFS for Patients With Hodgkin Lymphoma

March 7th 2024

Zanubrutinib Plus Obinutuzumab Granted Accelerated FDA Approval for R/R Follicular Lymphoma

December 22nd 2023

alloHSCT Yields Benefits in R/R AML Regardless of Leukemia Burden

Video Interviews
View All
November 21st 2023

New Therapeutic Approaches Are Needed to Improve High-Risk MCL Outcomes: Dr Amitkumar Mehta

October 15th 2023

Dr Alma Habib: Effort Needs to Be Put Into Addressing Disparities in Leukemia, Lymphoma Care

October 12th 2023

Dr Jennifer Vaughn: Value-Based Care Concerns Cost and Patient Experience

October 10th 2023

Dr Sarah Wall: Putting Attention on Older Adults With Blood-Based Cancer Is Vital Moving Forward

October 2nd 2023

Dr Adam Kittai Emphasizes 2 Crucial Reasons Value-Based Care Is Important for Blood-Based Cancers

July 25th 2023

Patients With CML Feel Shared Decision-Making Is Lacking, Want More Focus on QOL

July 20th 2023

Dr Wojciech Jurczak Discusses Changing Treatment Options for R/R DLBCL

July 11th 2023

Dr Fabian Lang Discusses Provider-Patient Communication in CML

July 7th 2023

Dr Fabian Lang on the Importance of Patient Involvement in CML Treatment Decisions

June 16th 2023

Dr Tycel Phillips on the Need for Novel Therapies for DLBCL

Podcasts
View All
February 3rd 2022

Lymphoma Research Foundation CEO on Biden’s Cancer Moonshot, Financial Toxicity

October 13th 2021

Keeping Patients With Cancer Out of the ED Through Dedicated Urgent Care

August 4th 2019

Podcast: This Week in Managed Care—Drug Importation Plan and Other Health News

Continuing Medical Education
View All
July 26th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 26th 2025

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

1.0 Credit / Oncology, Hematology, Hematologic Cancer
July 26th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
July 26th 2025

Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens

1.5 Credits / Hematologic Cancer, Hematology, Oncology
July 26th 2025

Exploring Therapeutic Advances in Myelofibrosis and Key Considerations for Effective Management

1.5 Credits / Oncology, Hematology

More News

Highlights from ASH 2023
December 20th 2023

ICYMI: Highlights From ASH 2023

Rose McNulty
The most-read content from the 2023 American Society of Hematology Annual Meeting and Exposition included the latest in treating hematologic malignancies, the hope brought by novel therapy strategies, and the potential for artificial intelligence to improve diagnostic accuracy.
Zanubrutinib rendering | Image credit: molekuul.be - stock.adobe.com
December 11th 2023

Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies

Conor Killmurray
Patients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.
Blood cells flowing | Image credit: Катерина Євтехова - stock.adobe.com
December 8th 2023

Health Care Resource Use, Cost Burden Appear Substantial in R/R B-Cell ALL

Russ Conroy
Treatment with blinatumomab or inotuzumab ozogamicin particularly confers higher total costs for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
FDA Investigating Reports of T-Cell Malignancies Following CAR T-Cell Therapy
November 28th 2023

FDA Investigating Reports of T-Cell Malignancies Following CAR T-Cell Therapy

AJMC Staff
The announcement applies to all currently approved therapies, both BCMA-directed and CD19-directed genetically modified autologous chimeric antigen receptor (CAR) T-cell treatments.
Blood Cells | Image credit: Катерина Євтехова - stock.adobe.com.jpg
November 25th 2023

Evolving Treatment Patterns Lead to Improved Outcomes in Relapsed/Refractory MCL

Kyle Doherty
Patients with relapsed/refractory mantle cell lymphoma have experienced event-free survival and overall survival benefits due to advances in second-line treatment approaches over time.
Image credit: LASZLO | stock.adobe.com
November 18th 2023

Base-Edited T Cells Could Minimize Immunotherapy Complications in Leukemia, Study Suggests

Aislinn Antrim
The use of base editing to generate universal, off-the-shelf CAR T cells is a promising approach for relapsed leukemia, with potential implications for the future of gene therapy.
CAR T cell AI-generated image | Image credit: AIGen - stock.adobe.com
November 17th 2023

Review Explores Link Between Tumor Burden, CAR T-Cell Therapy Efficacy

Rose McNulty
A recent review aimed to characterize the relationship between tumor burden and clinical outcomes in patients treated with chimeric antigen receptor (CAR) T-cell therapy, highlighting the potential mechanisms of high tumor burden impacting CAR T-cell failure.
Child laying in hospital bed | Image credit: wavebreak3 - stock.adobe.com.jpg
November 3rd 2023

High Disease Burden at Acute Leukemia Diagnosis More Common in Black Children, Study Finds

Rose McNulty
A study evaluating disparities among children with acute leukemia found that Black children are more likely to present with higher disease burden at diagnosis compared with non-Hispanic White children.
FDA Approved | Image credit: chrisdorney - stock.adobe.com
October 27th 2023

FDA Approves Bosutinib for Pediatric Patients With CP-CML

Nichole Tucker
Bosutinib has a new indication in leukemia as a well as a newly-approved formulation.
Mantle cell lymphoma Image credit: David A Litman - stock.adobe.com
October 23rd 2023

Zanubrutinib Associated With Better OS in Second vs Later Lines of R/R MCL Therapy

Rose McNulty
A pooled analysis with nearly 3 years of follow-up showed better outcomes when zanubrutinib was given in the second line vs later lines of therapy in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
High LDH Levels Associated With Worse Survival in Newly Diagnosed AML
October 13th 2023

High LDH Levels Associated With Worse Survival in Newly Diagnosed AML

Russ Conroy
Elevated white blood cell counts also appear to correlate with shorter overall survival in patients receiving standard induction chemotherapy plus cytarabine for acute myeloid leukemia.
Lymphoma | Image credit: Dr_Microbe - stock.adobe.com
October 6th 2023

Bridging RT Before CAR T-Cell Therapy Can Benefit Patients With R/R DLBCL

Rose McNulty
Researchers found that patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) may benefit from bridging radiation therapy (RT) ahead of receiving chimeric antigen receptor (CAR) T-cell therapy.
FDA Approved | Image credit: chrisdorney - stock.adobe.com
September 28th 2023

FDA Approves Bosutinib for Pediatric Chronic Myelogenous Leukemia

Hayley Virgil
Based on findings from the phase 1/2 BCHILD trial, the FDA approved bosutinib for pediatric chronic myelogenous leukemia.
DNA | Image credit: vitstudio - stock.adobe.com
September 22nd 2023

DNA Index Most Effectively Identifies Patients With Hyperdiploid ALL

Rose McNulty
The measure of total DNA in leukemic cells as defined by a DNA index outperformed other criteria for identifying patients with hyperdiploid acute lymphoblastic leukemia (ALL) and favorable prognosis.
Woman comforting another woman with cancer | Image credit: Photographee.eu - stock.adobe.com
September 21st 2023

Support and Follow-Up Are Needed to Combat Distress in Lymphoma

Hayley Virgil
Several discrepancies in care must be considered to properly address psychological needs in patients with lymphoma, including patient/doctor communication, information provision, and applying distress guidelines.
FDA approval stamp | Image credit: Olivier Le Moal - stock.adobe.com
September 15th 2023

FDA Approves Momelotinib for Myelofibrosis With Anemia

Rose McNulty
The agency's approval of momelotinib marks the first for both newly diagnosed and previously treated myelofibrosis with anemia.
Leukemia cell | Image credit: Dr_Microbe - stock.adobe.com
September 9th 2023

Ponatinib Plus Chemotherapy Elicits MRD-Negative Remissions in Certain Patients With ALL

Kyle Doherty
Ponatinib also produces an improvement in progression-free survival compared with imatinib among those with Philadelphia chromosome-positive acute lymphoblastic leukemia in the phase 3 PhALLCON trial.
Blood cells | Image credit: flashmovie - stock.adobe.com
September 8th 2023

AML-Specific Early Mortality Risk Indices May Increase Accuracy of Care Quality Measurements

Rose McNulty
A study found acute myeloid leukemia (AML) salvage therapy was independently associated with early mortality compared with frontline therapy, suggesting that algorithms measuring quality of care should incorporate risk mortality indices that factor in disease characteristics and treatment status.
Heart and stethescope
August 30th 2023

Cardiac Radiotherapy May Increase Late Disease Risk in Pediatric Cancer Survivors

Nicholas Wrigley
Increasing radiation doses to the whole heart appear to correlate with higher risks of valvular disease, coronary artery disease, and heart failure in childhood cancer survivors, a recent study found.
image of leukemia cell
August 29th 2023

Older Patients With AML Less Likely to Receive Genomic Testing, Study Finds

Pearl Steinzor
A study highlights an unmet need for patients with acute myeloid leukemia (AML) to access and afford genomic testing, especially among an older patient population.
Lymphoma cell
August 18th 2023

CAR T-Cell Therapy Shown Safe, Effective in MCL With CNS Involvement

Rose McNulty
A small study suggests the use of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with mantle cell lymphoma (MCL) with secondary central nervous system (CNS) involvement is safe and effective.
CAR T cells
August 12th 2023

Receiving More Therapies Prior to CAR T-Cell Therapy May Worsen Outcomes in NHL

Nicholas Wrigley
Findings from a retrospective analysis suggest an association between bridging therapy and poorer outcomes among patients with aggressive, relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).
Heart Health Image
August 10th 2023

Atorvastatin May Mitigate Risk of Cardiac Events Due to Anthracycline Use in Lymphoma

Rose McNulty
Anthracyclines are widely used to treat hematological and solid-tumor cancers, but past research suggests their use may be associated with late cardiac effects, including heart failure, among patients with lymphomas and other cancers.
ASCO 2023 logo
July 31st 2023

ASCO 2023: Leukemia and Lymphoma

Mary Caffrey Rose McNulty Jordyn Sava
Results include a landmark study that involved seamless collaboration across adult and pediatric patient groups, leading to a highly diverse study population. Other coverage addresses access to novel therapies and what's coming in the pipeline, including CAR T-cell therapy with tyrosine kinase inhibitors.
Higher Spleen Volume at HSCT Associated With Worse Outcomes in AML
July 21st 2023

Higher Spleen Volume at HSCT Associated With Worse Outcomes in AML

Rose McNulty
A recent study found that higher spleen volume before undergoing allogeneic hematopoietic stem cell transplantation (HSCT) was associated with worse overall survival and higher nonrelapse mortality incidence in patients with acute myeloid leukemia (AML).
FDA Accepts sNDA for Zanubrutinib Plus Obinutuzumab for R/R Follicular Lymphoma
July 12th 2023

FDA Accepts sNDA for Zanubrutinib Plus Obinutuzumab for R/R Follicular Lymphoma

Jordyn Sava
Following positive phase 2 results from the ROSEWOOD study, BeiGene is seeking FDA approval of zanubrutinib plus obinutuzumab for select patients with relapsed/refractory (R/R) follicular lymphoma.
Lab assistant, a medical scientist, a chemistry researcher holds a glass tube through the blood sample, does a chemical experiment and examines a patient's blood sample. Medicine and research concept: © PhotosD - stock.adobe.com
July 2nd 2023

Review Highlights Use of MRD in AML, ALL, CML

Gianna Melillo
Measurable residual disease (MRD) can predict disease progression in patients who have acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and chronic myeloid leukemia (CML).
acute lymphoblastic leukemia blasts
June 28th 2023

Looking Ahead at CAR T-Cell Therapy for R/R Acute Lymphoblastic Leukemia

Mary Caffrey
Presentations on the first day of the 2023 American Society of Clinical Oncology Annual Meeting covered data on a split dose CAR T-cell therapy and a CAR T therapy manufactured with TKI.
Genetically engineered chimeric antigen receptor immune cell with implanted gene strain - 3d illustration: © Christoph Burgstedt - stock.adobe.com
June 27th 2023

Real-World Evidence Shows CAR T-Cell Therapy Effective in Older Patients With Relapsed/Refractory DLBCL

Jared Kaltwasser
The therapy is still not widely used among older patients who have diffuse large B-cell lymphoma (DLBCL).
Study Explores Real-World BTK Inhibitor Use Patterns in Mantle Cell Lymphoma
June 24th 2023

Study Explores Real-World BTK Inhibitor Use Patterns in Mantle Cell Lymphoma

The study was conducted to provide insight into real-world Bruton tyrosine kinase (BTK) inhibitor treatment patterns in mantle cell lymphoma, as current data are limited.
12345678
...
19>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo